Cargando…

Epidemiology, clinical characteristics and treatment of critically ill patients with COVID-19): a protocol for a living systematic review

INTRODUCTION: In December 2019, the first cases of COVID-19 associated with SARS-CoV-2 viral infection were described in Wuhan, Hubei Province, China. Since then, it has spread rapidly affecting 188 countries and was declared a pandemic by the WHO on 11 March 2020. Preliminary reports suggest up to...

Descripción completa

Detalles Bibliográficos
Autores principales: Milovanovic, Lazar, Hessey, Erin, Sebastianski, Meghan, Keto-Lambert, Diana, Vandermeer, Ben, Bagshaw, Sean M, Rewa, Oleksa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786544/
https://www.ncbi.nlm.nih.gov/pubmed/33402406
http://dx.doi.org/10.1136/bmjopen-2020-042008
_version_ 1783632647861305344
author Milovanovic, Lazar
Hessey, Erin
Sebastianski, Meghan
Keto-Lambert, Diana
Vandermeer, Ben
Bagshaw, Sean M
Rewa, Oleksa
author_facet Milovanovic, Lazar
Hessey, Erin
Sebastianski, Meghan
Keto-Lambert, Diana
Vandermeer, Ben
Bagshaw, Sean M
Rewa, Oleksa
author_sort Milovanovic, Lazar
collection PubMed
description INTRODUCTION: In December 2019, the first cases of COVID-19 associated with SARS-CoV-2 viral infection were described in Wuhan, Hubei Province, China. Since then, it has spread rapidly affecting 188 countries and was declared a pandemic by the WHO on 11 March 2020. Preliminary reports suggest up to 30% of patients require intensive care unit (ICU) admission and case fatality rate estimate is 2.3%–7.2%. The primary reason for ICU admission is hypoxaemic respiratory failure, while factors associated with ICU admission include increased age, presence of comorbidities and cytokine storm. Case series and retrospective trials initially assessed proposed treatments with randomised controlled trials now reporting early outcomes. We conduct a systematic review and meta-analysis to identify epidemiological factors, treatments and complications that predict mortality among critically ill patients with COVID-19. METHODS AND ANALYSIS: Our comprehensive search strategy was developed in consultation with a research librarian. We will search electronic databases: Ovid Medline, Ovid Embase, Ovid Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Wiley Cochrane Library. The search strategy combines concepts from COVID-19, validated COVID-19 search filters and geographical locations of large outbreaks. Citation screening, selection, quality assessment and data abstraction will be performed in duplicate. Clinically homogenous epidemiological characteristics, interventions and complications will be pooled in statistical meta-analysis. Within the framework of a living systematic review, the search and data analysis will be updated every 6 months. ETHICS AND DISSEMINATION: Our systematic review will synthesise literature on risk factors and interventions associated with mortality in critically ill patients with COVID-19. Results will be presented at national and international conferences and submitted for peer-reviewed publication. The pooled analysis can provide guidance to inform clinical guidelines for care of critically ill patients with COVID-19. Iterative updates will be made public through open access. Research ethics approval is not required. PROSPERO REGISTRATION NUMBER: CRD42020176672.
format Online
Article
Text
id pubmed-7786544
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-77865442021-01-07 Epidemiology, clinical characteristics and treatment of critically ill patients with COVID-19): a protocol for a living systematic review Milovanovic, Lazar Hessey, Erin Sebastianski, Meghan Keto-Lambert, Diana Vandermeer, Ben Bagshaw, Sean M Rewa, Oleksa BMJ Open Intensive Care INTRODUCTION: In December 2019, the first cases of COVID-19 associated with SARS-CoV-2 viral infection were described in Wuhan, Hubei Province, China. Since then, it has spread rapidly affecting 188 countries and was declared a pandemic by the WHO on 11 March 2020. Preliminary reports suggest up to 30% of patients require intensive care unit (ICU) admission and case fatality rate estimate is 2.3%–7.2%. The primary reason for ICU admission is hypoxaemic respiratory failure, while factors associated with ICU admission include increased age, presence of comorbidities and cytokine storm. Case series and retrospective trials initially assessed proposed treatments with randomised controlled trials now reporting early outcomes. We conduct a systematic review and meta-analysis to identify epidemiological factors, treatments and complications that predict mortality among critically ill patients with COVID-19. METHODS AND ANALYSIS: Our comprehensive search strategy was developed in consultation with a research librarian. We will search electronic databases: Ovid Medline, Ovid Embase, Ovid Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Wiley Cochrane Library. The search strategy combines concepts from COVID-19, validated COVID-19 search filters and geographical locations of large outbreaks. Citation screening, selection, quality assessment and data abstraction will be performed in duplicate. Clinically homogenous epidemiological characteristics, interventions and complications will be pooled in statistical meta-analysis. Within the framework of a living systematic review, the search and data analysis will be updated every 6 months. ETHICS AND DISSEMINATION: Our systematic review will synthesise literature on risk factors and interventions associated with mortality in critically ill patients with COVID-19. Results will be presented at national and international conferences and submitted for peer-reviewed publication. The pooled analysis can provide guidance to inform clinical guidelines for care of critically ill patients with COVID-19. Iterative updates will be made public through open access. Research ethics approval is not required. PROSPERO REGISTRATION NUMBER: CRD42020176672. BMJ Publishing Group 2021-01-05 /pmc/articles/PMC7786544/ /pubmed/33402406 http://dx.doi.org/10.1136/bmjopen-2020-042008 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Intensive Care
Milovanovic, Lazar
Hessey, Erin
Sebastianski, Meghan
Keto-Lambert, Diana
Vandermeer, Ben
Bagshaw, Sean M
Rewa, Oleksa
Epidemiology, clinical characteristics and treatment of critically ill patients with COVID-19): a protocol for a living systematic review
title Epidemiology, clinical characteristics and treatment of critically ill patients with COVID-19): a protocol for a living systematic review
title_full Epidemiology, clinical characteristics and treatment of critically ill patients with COVID-19): a protocol for a living systematic review
title_fullStr Epidemiology, clinical characteristics and treatment of critically ill patients with COVID-19): a protocol for a living systematic review
title_full_unstemmed Epidemiology, clinical characteristics and treatment of critically ill patients with COVID-19): a protocol for a living systematic review
title_short Epidemiology, clinical characteristics and treatment of critically ill patients with COVID-19): a protocol for a living systematic review
title_sort epidemiology, clinical characteristics and treatment of critically ill patients with covid-19): a protocol for a living systematic review
topic Intensive Care
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786544/
https://www.ncbi.nlm.nih.gov/pubmed/33402406
http://dx.doi.org/10.1136/bmjopen-2020-042008
work_keys_str_mv AT milovanoviclazar epidemiologyclinicalcharacteristicsandtreatmentofcriticallyillpatientswithcovid19aprotocolforalivingsystematicreview
AT hesseyerin epidemiologyclinicalcharacteristicsandtreatmentofcriticallyillpatientswithcovid19aprotocolforalivingsystematicreview
AT sebastianskimeghan epidemiologyclinicalcharacteristicsandtreatmentofcriticallyillpatientswithcovid19aprotocolforalivingsystematicreview
AT ketolambertdiana epidemiologyclinicalcharacteristicsandtreatmentofcriticallyillpatientswithcovid19aprotocolforalivingsystematicreview
AT vandermeerben epidemiologyclinicalcharacteristicsandtreatmentofcriticallyillpatientswithcovid19aprotocolforalivingsystematicreview
AT bagshawseanm epidemiologyclinicalcharacteristicsandtreatmentofcriticallyillpatientswithcovid19aprotocolforalivingsystematicreview
AT rewaoleksa epidemiologyclinicalcharacteristicsandtreatmentofcriticallyillpatientswithcovid19aprotocolforalivingsystematicreview